NEW YORK--(BUSINESS WIRE)--Regulatory News:
Date: September 11, 2014
Time: 8:00 AM
Location: Le Parker Meridien Hotel - 119 West 56th Street - NEW YORK
Cellectis' scientists will be attending in New York to present the Company's therapeutic innovations.
- State-of-the-art genome engineering technologies
- New CAR (Chimeric Antigen Receptor) architecture
- Allogeneic cGMP manufacturing process for CART products
Please RSVP with
Upon invitation – limited seats available
Cellectis is a biopharmaceutical company focused on oncology. The company’s mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Cellectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN™, meganucleases and the state-of-the-art electroporation technology Pulse Agile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Cellectis adoptive cancer immunotherapy for chronic and acute leukemias is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Cellectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com.